rd (April, 2016) - $3.8M / Covered 80% of all pre-clinical development costs • Clinical grant application — (Q2, 2017) — up to $5M / Covers 70% of Phaselb Clinical trial costs Therapeutic focus: • Rebuild new blood and immune system by transplanting E-CEL cord blood stem cells (transplantation) in high-risk l